Insiders At Lockheed Martin Sold US$7.7m In Stock, Alluding To Potential Weakness
Over the past year, many Lockheed Martin Corporation (NYSE:LMT) insiders sold a significant stake in the company which may have piqued investors' interest. When evaluating insider transactions, knowing whether insiders are buying is usually more beneficial than knowing whether they are selling, as the latter can be open to many interpretations. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period.
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.
Over the last year, we can see that the biggest insider sale was by the President of Rotary & Mission Systems, Stephanie Hill, for US$2.1m worth of shares, at about US$443 per share. So it's clear an insider wanted to take some cash off the table, even below the current price of US$468. We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. However, while insider selling is sometimes discouraging, it's only a weak signal. This single sale was just 26% of Stephanie Hill's stake.
In the last year Lockheed Martin insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
See our latest analysis for Lockheed Martin
If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.
The last three months saw significant insider selling at Lockheed Martin. Specifically, insiders ditched US$3.9m worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain.
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 0.07% of Lockheed Martin shares, worth about US$79m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
Insiders sold stock recently, but they haven't been buying. Looking to the last twelve months, our data doesn't show any insider buying. Insiders own shares, but we're still pretty cautious, given the history of sales. We're in no rush to buy! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 2 warning signs with Lockheed Martin and understanding these should be part of your investment process.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Amerant Bancorp (NYSE:AMTB) shareholders have endured a 38% loss from investing in the stock three years ago
For many investors, the main point of stock picking is to generate higher returns than the overall market. But the risk of stock picking is that you will likely buy under-performing companies. Unfortunately, that's been the case for longer term Amerant Bancorp Inc. (NYSE:AMTB) shareholders, since the share price is down 41% in the last three years, falling well short of the market return of around 57%. Furthermore, it's down 22% in about a quarter. That's not much fun for holders. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. Over the three years that the share price declined, Amerant Bancorp's earnings per share (EPS) dropped significantly, falling to a loss. Due to the loss, it's not easy to use EPS as a reliable guide to the business. However, we can say we'd expect to see a falling share price in this scenario. The image below shows how EPS has tracked over time (if you click on the image you can see greater detail). Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here. When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, Amerant Bancorp's TSR for the last 3 years was -38%, which exceeds the share price return mentioned earlier. And there's no prize for guessing that the dividend payments largely explain the divergence! While the broader market gained around 12% in the last year, Amerant Bancorp shareholders lost 18% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Longer term investors wouldn't be so upset, since they would have made 5%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Amerant Bancorp you should know about. If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Bloomberg
29 minutes ago
- Bloomberg
Investors Set to Flock to Safety as World Awaits Iran's Response
Traders are forecasting a drop in stocks, a jump in crude prices and possibly a strengthening of the dollar as investors head for safety in the wake of the US attack on Iran's three main nuclear sites. Concern that the war will intensify even further is likely to push equity prices lower, while bonds may get a boost, market watchers say. The moves will be bigger if Iran responds with steps such as blocking the Strait of Hormuz, a key passage for oil and gas shipments, or attacking US forces in the region, they say.
Yahoo
an hour ago
- Yahoo
Should You Buy Emera While it's Below $65?
Written by Chris MacDonald at The Motley Fool Canada A Canadian utility stock I don't discuss enough (but probably should), Emera (TSX:EMA) is a stock with a chart that most investors would certainly be okay with owning for a significant period of time. The utility giant has continued to see strong growth, as Emera continues to focus on expanding into new markets (most notably Florida), and capital flows continue to remain positive for the company, which was recently listed on the NYSE in May. The question moving forward is whether this is a utility stock that could be due for a new all-time high. With the company's previous high of around $65 per share now in range, the question is whether this stock is a buy (headed to new all-time highs) or if investors should take profits. Let's dive in. One of the things I like most about the utility sector is the sheer defensive nature of this sector. We all need electricity and heat, and Emera is a key player in this regard (and now that it's a dual-listed stock, investors from all over North America can buy). But in the case of Emera, I think the company's fundamentals really stand out as the key reason why this stock has rallied in the way it has. Aside from the company's durable and foundationally strong dividend yield of 4.7%, there's a lot to like about the company's capital investment plan. Emera is set to put $20 billion to work over the next four years, targeting grid modernization and infrastructure growth in key high-performing markets such as Florida. We'll have to see how Emera's earnings growth trajectory shifts over this time frame. But looking at the company's most recent results, it's clear that the company's management team is doing something right. With overall earnings per share growth expected to come in at the 5% to 7% range for the coming years (and regulated utility investments generally perceived to return around 8%), I think there's still upside with Emera at its current stock price. For long-term investors, this is a company I think is certainly worth considering. I think Emera is one of those stocks that's going to continue to demand a premium in today's market. The defensiveness this company provides, in addition to its robust yield (and solid payout ratio to boot), makes this a name I'd personally consider below the $65 level. I think new all-time highs are in order, but investors may need to be patient with this name. I'm going to keep this stock on my watch list and be patient. I think anything can happen in this market, and most investors would likely agree. But for those with a long-term investing time horizon, dollar cost averaging into such a name may make sense. Emera looks like a solid pick in this current market, and it's one I'd consider a contender for a top portfolio holding right now. The post Should You Buy Emera While it's Below $65? appeared first on The Motley Fool Canada. More reading Made in Canada: 5 Homegrown Stocks Ready for the 'Buy Local' Revolution [PREMIUM PICKS] Market Volatility Toolkit Best Canadian Stocks to Buy in 2025 Beginner Investors: 4 Top Canadian Stocks to Buy for 2025 5 Years From Now, You'll Probably Wish You Grabbed These Stocks Subscribe to Motley Fool Canada on YouTube Fool contributor Chris MacDonald has no position in any of the stocks mentioned. The Motley Fool recommends Emera. The Motley Fool has a disclosure policy. 2025
